According to , recently published report ‘Opium (Opioid) Addiction – Pipeline Review, H2 2016’; Opium (Opioid) Addiction pipeline therapeutics constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes.
Request for sample @ https://marketreportscenter.com/request-sample/438514
Furthermore, research says; Opium (Opioid) Addiction Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.
Check Discount on report @ https://marketreportscenter.com/request-discount/438514
The report ‘Opium (Opioid) Addiction – Pipeline Review, H2 2016’ outlays comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 4, 3, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
For more details of report, table of content, purchase copy of report visit https://marketreportscenter.com/reports/438514/opium-opioid-addiction-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center